Biopharmaceuticals Contract Manufacturing Market to Reach USD 90.02 Billion by 2030, Driven by Outsourcing of Biologics and Production Innovation

Mordor Intelligence has published a new report on the Biopharmaceuticals Contract Manufacturing Market, offering a comprehensive analysis of trends, growth drivers, and future projections.

Introduction

The global biopharmaceuticals contract manufacturing market is projected to rise from USD 47.42 billion in 2025 to USD 90.02 billion by 2030, at a compound annual growth rate (CAGR) of 13.68%. This surge reflects growing reliance on contract development and manufacturing organizations (CDMOs) as biopharma companies aim to optimize capital efficiency and access specialized production facilities.

CDMOs now play a crucial role in producing biologics and biosimilars-leveraging skills in single-use systems and gene therapy vector manufacturing. Both established pharmaceutical companies and biotech startups are placing greater trust in CDMOs to handle sensitive biologic pipelines, as internal setups become increasingly complex and costly.

Report Overview: https://www.mordorintelligence.com/industry-reports/biopharmaceuticals-contract-manufacturing-market?utm_source=openpr

Key Trends

1. Outsourcing Driven by Complex Biologics Pipelines
Large biopharma sponsors are offloading production responsibilities to CDMOs to allocate more resources toward R&D and commercialization. The complexity of modern biologics-such as monoclonal antibodies and gene therapies-often exceeds in-house capacity, making CDMOs the preferred partners.

2. Rise of Single-Use and Modular Facilities
CDMOs are adopting single-use bioprocessing systems and modular cleanroom designs that allow rapid scale-up and flexible production. This flexibility is especially critical during clinical development phases and rapid response needs-such as vaccine production during the pandemic.

3. Growing Cell and Gene Therapy Manufacturing
The segment related to cell and gene therapy vectors is expanding at an impressive CAGR of around 18.4%, even though antibodies remain the dominant product class . Specialized vector capabilities, viral and non-viral, are now core offerings of many CDMOs.

4. North America's Leading Position, Asia-Pacific Gains Ground
North America continues to lead with 36.7% of the market, thanks to its mature biotech ecosystem. Meanwhile, Asia-Pacific is the fastest-growing region, benefiting from pharmaceutical companies adopting "China‐plus‐one" strategies and expanding regional production capabilities.

5. Investment in Digital Biomanufacturing
CDMOs are investing in AI-driven control systems, predictive analytics, and continuous processing technologies. These technologies improve batch consistency, reduce time-to-market, and support regulatory compliance-advantages that attract more clients.

Market Segmentation

By Product Type

Peptides/Proteins

Antibodies (mAbs & ADCs)

Vaccines

Biosimilars

Other Biologics

By Service Type

Process Development

cGMP Drug Substance Manufacturing

Fill-Finish & Lyophilization

Analytical & QC Services

Packaging & Logistics

By Expression System

Mammalian

Microbial

Insect & Plant

By Development Phase

Pre-clinical

Phase I

Phase II

Phase III & Commercial



By Geography

North America

Asia-Pacific

Europe

South America

Middle East & Africa

Explore Our Full Library of Healthcare Industry Research Reports: https://www.mordorintelligence.com/market-analysis/healthcare?utm_source=openpr



Key Players

Major companies leading the biopharmaceuticals contract manufacturing market include:

Boehringer Ingelheim GmbH

Lonza Group

Samsung Biologics

WuXi Biologics

Thermo Fisher Scientific Inc.



These entities have built capacity in mammalian cell culture, microbial systems, and viral vector platforms. They combine global footprints with strong service pipelines-process development, clinical to commercial scale-up, and regulatory support.

Notably, Samsung Biologics, a global CDMO headquartered in South Korea, has rapidly expanded its manufacturing footprint. With major biopharma collaborations-including Pfizer, Moderna, GSK, Lilly, and AstraZeneca-Samsung's four plants (and ongoing fifth expansion) highlight the scale and significance of leading CDMOs.


Conclusion

The biopharmaceuticals contract manufacturing market is entering a period of rapid expansion, expected to nearly double from USD 47.42 billion in 2025 to USD 90.02 billion by 2030. Demand remains strong for biologics CDMOs with expertise in highly regulated, complex production formats such as antibodies, gene therapies, and vaccines.

Key drivers include outsourcing of pipeline stages, adoption of single-use and flexible facilities, and advanced manufacturing analytics. As North America maintains leadership, Asia-Pacific is emerging as a hotspot for strategic capacity expansion. CDMOs investing in specialized infrastructure and digital systems are best positioned to lead this market and support the biopharma industry's dynamic roadmap ahead.

Industry Related Reports:

Biopharmaceutical Contract Research and Manufacturing Services (CRAMS) Market: The Biopharmaceutical CRAMS Market report segments the industry into By Service Type (Manufacturing, Research), By Therapeutic Area (Cardiovascular, Infectious Diseases, Endocrine Diseases, Oncology, and more), By End-User (Pharmaceutical and Biopharmaceutical Companies, Medical Device Companies, and more), and Geography (North America, Europe, and more).
Get more insights: https://www.mordorintelligence.com/industry-reports/biopharmaceutical-contract-research-and-manufacturing-services-crams-market?utm_source=openpr

Biosimilar Contract Manufacturing Market: The Biosimilar Contract Manufacturing Market report segments the industry into By Production Technology (Mammalian, Microbial), By Product (Recombinant Non-glycosylated Proteins, and more), By Application (Oncology, Infectious Diseases, Blood Disorders, and more), By Service Type (Upstream Processing, Downstream Processing, and more), and Geography (North America, Europe, and more).
Get more insights: https://www.mordorintelligence.com/industry-reports/biosimilar-contract-manufacturing-market?utm_source=openpr

Pharmaceutical Contract Manufacturing & Research Services Market: The Pharmaceutical Contract Manufacturing And Research Services Market report segments the industry into By Manufacturing Services (API/Bulk Drugs, Advanced Drug Delivery Formulations Packaging, Packaging, Finished Dose Formulations), By Research Services (Oncology, Vaccines, Inflammation And Immunology, Cardiology, and more), and Geography (North America, Europe, Asia-Pacific, and more).
Get more insights: https://www.mordorintelligence.com/industry-reports/pharmaceutical-contract-manufacturing-and-research-services?utm_source=openpr

About Mordor Intelligence:

Mordor Intelligence is a trusted partner for businesses seeking comprehensive and actionable market intelligence. Our global reach, expert team, and tailored solutions empower organizations and individuals to make informed decisions, navigate complex markets, and achieve their strategic goals.

With a team of over 550 domain experts and on-ground specialists spanning 150+ countries, Mordor Intelligence possesses a unique understanding of the global business landscape. This expertise translates into comprehensive syndicated and custom research reports covering a wide spectrum of industries, including aerospace & defense, agriculture, animal nutrition and wellness, automation, automotive, chemicals & materials, consumer goods & services, electronics, energy & power, financial services, food & beverages, healthcare, hospitality & tourism, information & communications technology, investment opportunities, and logistics.

For any inquiries or to access the full report, please contact:

media@mordorintelligence.com
https://www.mordorintelligence.com/

Mordor Intelligence, 11th Floor, Rajapushpa Summit, Nanakramguda Rd, Financial District, Gachibowli, Hyderabad, Telangana - 500032, India

Mordor Intelligence is a trusted partner for businesses seeking comprehensive and actionable market intelligence. Our global reach, expert team, and tailored solutions empower organizations and individuals to make informed decisions, navigate complex markets, and achieve their strategic goals.

With a team of over 550 domain experts and on-ground specialists spanning 150+ countries, Mordor Intelligence possesses a unique understanding of the global business landscape. This expertise translates into comprehensive syndicated and custom research reports covering a wide spectrum of industries, including aerospace & defense, agriculture, animal nutrition and wellness, automation, automotive, chemicals & materials, consumer goods & services, electronics, energy & power, financial services, food & beverages, healthcare, hospitality & tourism, information & communications technology, investment opportunities, and logistics.

For any inquiries or to access the full report, please contact:

media@mordorintelligence.com
https://www.mordorintelligence.com/

This release was published on openPR.